GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » ARYA Sciences Acquisition Corp II (NAS:ARYBU) » Definitions » Cash Flow from Financing

ARYA Sciences Acquisition II (ARYA Sciences Acquisition II) Cash Flow from Financing : $0.00 Mil (TTM As of Jun. 2020)


View and export this data going back to 2020. Start your Free Trial

What is ARYA Sciences Acquisition II Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the six months ended in Jun. 2020, ARYA Sciences Acquisition II paid $0.00 Mil more to buy back shares than it received from issuing new shares. It received $0.00 Mil from issuing more debt. It paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares. It received $0.00 Mil from paying cash dividends to shareholders. It received $0.00 Mil on other financial activities. In all, ARYA Sciences Acquisition II spent $0.00 Mil on financial activities for the six months ended in Jun. 2020.


ARYA Sciences Acquisition II Cash Flow from Financing Historical Data

The historical data trend for ARYA Sciences Acquisition II's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ARYA Sciences Acquisition II Cash Flow from Financing Chart

ARYA Sciences Acquisition II Annual Data
Trend
Cash Flow from Financing

ARYA Sciences Acquisition II Semi-Annual Data
Feb20 Mar20 Jun20
Cash Flow from Financing - - -

ARYA Sciences Acquisition II Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

ARYA Sciences Acquisition II's Cash from Financing for the fiscal year that ended in . 20 is calculated as:

ARYA Sciences Acquisition II's Cash from Financing for the quarter that ended in Jun. 2020 is:


For stock reported annually, GuruFocus uses latest annual data as the TTM data. Cash Flow from Financing for the trailing twelve months (TTM) ended in Jun. 2020 was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ARYA Sciences Acquisition II  (NAS:ARYBU) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

ARYA Sciences Acquisition II's issuance of stock for the six months ended in Jun. 2020 was $0.00 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

ARYA Sciences Acquisition II's repurchase of stock for the six months ended in Jun. 2020 was $0.00 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

ARYA Sciences Acquisition II's net issuance of debt for the six months ended in Jun. 2020 was $0.00 Mil. ARYA Sciences Acquisition II received $0.00 Mil from issuing more debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

ARYA Sciences Acquisition II's net issuance of preferred for the six months ended in Jun. 2020 was $0.00 Mil. ARYA Sciences Acquisition II paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

ARYA Sciences Acquisition II's cash flow for dividends for the six months ended in Jun. 2020 was $0.00 Mil. ARYA Sciences Acquisition II received $0.00 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

ARYA Sciences Acquisition II's other financing for the six months ended in Jun. 2020 was $0.00 Mil. ARYA Sciences Acquisition II received $0.00 Mil on other financial activities.


ARYA Sciences Acquisition II Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of ARYA Sciences Acquisition II's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.


ARYA Sciences Acquisition II (ARYA Sciences Acquisition II) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
51 Astor Place, 10th Floor, New York, NY, USA, 10003
Website
ARYA Sciences Acquisition Corp II is a blank check company.
Executives
Joseph Edelman director C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Advisors Llc director 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Life Sciences Master Fund Ltd director C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Adam Leo Stone director, officer: Chief Executive Officer C/O SOLID BIOSCIENCES, LLC, 141 PORTLAND STREET, FIFTH FLOOR, CAMBRIDGE MA 02139
Michael Seth Altman director, officer: Chief Financial Officer C/O PERCEPTIVE ADVISORS, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Arya Sciences Holdings Ii 10 percent owner 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Todd Wider director 4848 LEMMON AVENUE, SUITE 517, DALLAS TX 75219
Jake Bauer director C/O MYOKARDIA, INC., 333 ALLERTON AVENUE, SOUTH SAN FRANCISCO CA 94080
Konstantin Poukalov officer: Chief Business Officer C/O KADMON HOLDINGS, LLC, 450 E 29TH STREET, NEW YORK NY 10016
Chad M Robins director C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102